psalexa

Biosimilars Market By Product (Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, Recombinant Peptides), Technology (mAb, rDNA, Bioassays, Nuclear Magnetic Resonance, Electrophoresis), Indication (Oncology, Rheumatology, Blood-Related Disorders, Auto-Immune Diseases, Chronic Diseases, Infectious Diseases, Growth Hormone Deficiency), Route of Administration (Intravenous, Subcutaneous, Intranasal), Geographical Outlook – Trends Analysis and Growth Forecast to 2024

  • Published: April 2019
  • Report Code: LS10997
  • Available Format: PDF
  • Pages: 187

Chapter 1. Research Background

1.1 Research Objectives

1.2 Market Definition

1.3 Research Scope

1.3.1 Market Segmentation by Product

1.3.2 Market Segmentation by Technology

1.3.3 Market Segmentation by Indication

1.3.4 Market Segmentation by Manufacturing Type

1.3.5 Market Segmentation by Route of Administration (ROA)

1.3.6 Market Segmentation by Geography

1.3.7 Analysis Period

1.3.8 Market Data Reporting Unit

1.3.8.1 Value

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By region

2.2.1.2 By industry participant

2.2.1.3 By company type

2.3 Market Size Estimation

2.4 Data Triangulation

2.5 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction

4.1 Definition of Market Segments

4.1.1 By Product

4.1.1.1 Recombinant glycosylated proteins

4.1.1.1.1 mAbs

4.1.1.1.2 Erythropoietin

4.1.1.1.3 Follitropin

4.1.1.2 Recombinant non-glycosylated proteins

4.1.1.2.1 Insulin

4.1.1.2.2 Recombinant human growth hormone

4.1.1.2.3 G-CSF

4.1.1.2.4 Interferons

4.1.1.3 Recombinant peptides

4.1.2 By Technology

4.1.2.1 mAb

4.1.2.2 rDNA

4.1.2.3 Bioassays

4.1.2.4 NMR

4.1.2.5 Electrophoresis

4.1.3 By Indication

4.1.3.1 Oncology

4.1.3.2 Rheumatology

4.1.3.3 Blood-related disorders

4.1.3.4 Auto-immune diseases

4.1.3.5 Chronic diseases

4.1.3.6 Infectious diseases

4.1.3.7 GHD

4.1.3.8 Others

4.1.4 By Manufacturing Type

4.1.4.1 Contract

4.1.4.2 In-house

4.1.5 By ROA

4.1.5.1 Intravenous

4.1.5.2 Subcutaneous

4.1.5.3 Intranasal

4.1.5.4 Others

4.2 Market Dynamics

4.2.1 Trends

4.2.1.1 Increasing number of collaborations and partnerships

4.2.1.2 Rapid product launches

4.2.2 Drivers

4.2.2.1 Growing geriatric population

4.2.2.2 Increasing prevalence of chronic diseases

4.2.2.3 Increasing R&D investment by biopharmaceutical companies and extensive pipeline of biosimilars

4.2.2.4 Inexpensive nature of biosimilar drugs

4.2.2.5 Impact analysis of drivers on market forecast

4.2.3 Restraints

4.2.3.1 Complex manufacturing process

4.2.3.2 Strict regulations and delays in approvals

4.3 Porter’s Five Forces Analysis

4.4 Pricing Policies for Biosimilars

4.5 Pricing Scenario for Biosimilars

4.6 Positive Attributes for Biosimilar Pricing

Chapter 5. Global Market Size and Forecast

5.1 By Product

5.1.1 Recombinant Glycosylated Proteins Market, by Type

5.1.2 Recombinant Non-Glycosylated Proteins Market, by Type

5.2 By Technology

5.3 By Indication

5.4 By Manufacturing Type

5.5 By ROA

5.6 By Region

Chapter 6. Europe Market Size and Forecast

6.1 By Product

6.1.1 Recombinant Glycosylated Proteins Market, by Type

6.1.2 Recombinant Non-Glycosylated Proteins Market, by Type

6.2 By Technology

6.3 By Indication

6.4 By Manufacturing Type

6.5 By ROA

6.6 By Country

Chapter 7. APAC Market Size and Forecast

7.1 By Product

7.1.1 Recombinant Glycosylated Proteins Market, by Type

7.1.2 Recombinant Non-Glycosylated Proteins Market, by Type

7.2 By Technology

7.3 By Indication

7.4 By Manufacturing Type

7.5 By ROA

7.6 By Country

Chapter 8. North America Market Size and Forecast

8.1 By Product

8.1.1 Recombinant Glycosylated Proteins Market, by Type

8.1.2 Recombinant Non-Glycosylated Proteins Market, by Type

8.2 By Technology

8.3 By Indication

8.4 By Manufacturing Type

8.5 By ROA

8.6 By Country

Chapter 9. LATAM Market Size and Forecast

9.1 By Product

9.1.1 Recombinant Glycosylated Proteins Market, by Type

9.1.2 Recombinant Non-Glycosylated Proteins Market, by Type

9.2 By Technology

9.3 By Indication

9.4 By Manufacturing Type

9.5 By ROA

9.6 By Country

Chapter 10. MEA Market Size and Forecast

10.1 By Product

10.1.1 Recombinant Glycosylated Proteins Market, by Type

10.1.2 Recombinant Non-Glycosylated Proteins Market, by Type

10.2 By Technology

10.3 By Indication

10.4 By Manufacturing Type

10.5 By ROA

10.6 By Country

Chapter 11. Competitive Landscape

11.1 Benchmarking of Key Players Based on Indication

11.2 Global Strategic Development of Key Players

11.2.1 Product Launches

11.2.2 Geographic Expansions

Chapter 12. Company Profiles

12.1 AMEGA Biotech

12.1.1 Business Overview

12.1.2 Product and Service Offerings

12.2 Samsung Bioepis Co. Ltd.

12.2.1 Business Overview

12.2.2 Product and Service Offerings

12.3 Coherus BioSciences Inc.

12.3.1 Business Overview

12.3.2 Product and Service Offerings

12.3.3 Key Financial Summary

12.4 Synthon Holding B.V.

12.4.1 Business Overview

12.4.2 Product and Service Offerings

12.5 BIOCAD

12.5.1 Business Overview

12.5.2 Product and Service Offerings

12.5.2.1 Marketed products

12.5.2.2 Pipeline products

12.6 Zydus Cadila

12.6.1 Business Overview

12.6.2 Product and Service Offerings

12.6.3 Key Financial Summary

12.7 Celltrion Inc.

12.7.1 Business Overview

12.7.2 Product and Service Offerings

12.7.2.1 Marketed products

12.7.2.2 Pipeline products

12.7.3 Key Financial Summary

12.8 Dr. Reddy’s Laboratories Ltd.

12.8.1 Business Overview

12.8.2 Product and Service Offerings

12.8.3 Key Financial Summary

12.9 Teva Pharmaceutical Industries Limited

12.9.1 Business Overview

12.9.2 Product and Service Offerings

12.9.3 Key Financial Summary

12.10 Novartis AG

12.10.1 Business Overview

12.10.2 Product and Service Offerings

12.10.2.1 Marketed products

12.10.2.2 Pipeline products

12.10.3 Key Financial Summary

12.11 Pfizer Inc.

12.11.1 Business Overview

12.11.2 Product and Service Offerings

12.11.2.1 Marketed products

12.11.2.2 Pipeline products

12.11.3 Key Financial Summary

12.12 Mylan N.V.

12.12.1 Business Overview

12.12.2 Product and Service Offerings

12.12.3 Key Financial Summary

Chapter 13. Appendix

13.1 Abbreviations

13.2 Sources and References

13.3 Related Reports

 

LIST OF TABLES

 

TABLE 1 ANALYSIS PERIOD OF THE STUDY

TABLE 2 PRICE COMPARISON BETWEEN BIOSIMILARSS AND BIOLOGICS

TABLE 3 DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 4 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

TABLE 5 PRICE OF KEY BIOSIMILARS

TABLE 6 BIOSIMILARS ADAPTABILITY- COUNTRY-WISE ANALYSIS

TABLE 7 GLOBAL BIOSIMILARS MARKET, BY PRODUCT, $M (2014–2018)

TABLE 8 GLOBAL BIOSIMILARS MARKET, BY PRODUCT, $M (2019–2024)

TABLE 9 GLOBAL RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014–2018)

TABLE 10 GLOBAL RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2019–2024)

TABLE 11 GLOBAL RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014–2018)

TABLE 12 GLOBAL RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2019–2024)

TABLE 13 GLOBAL BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2014–2018)

TABLE 14 GLOBAL BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2019–2024)

TABLE 15 GLOBAL BIOSIMILARS MARKET, BY INDICATION, $M (2014–2018)

TABLE 16 GLOBAL BIOSIMILARS MARKET, BY INDICATION, $M (2019–2024)

TABLE 17 GLOBAL BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2014–2018)

TABLE 18 GLOBAL BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2019–2024)

TABLE 19 GLOBAL BIOSIMILARS MARKET, BY ROA, $M (2014–2018)

TABLE 20 GLOBAL BIOSIMILARS MARKET, BY ROA, $M (2019–2024)

TABLE 21 GLOBAL BIOSIMILARS MARKET, BY REGION, $M (2014–2018)

TABLE 22 GLOBAL BIOSIMILARS MARKET, BY REGION, $M (2019–2024)

TABLE 23 EUROPEAN MEDICINES AGENCY (EMA) APPROVED BIOSIMILARS

TABLE 24 EUROPE BIOSIMILARS MARKET, BY PRODUCT, $M (2014–2018)

TABLE 25 EUROPE BIOSIMILARS MARKET, BY PRODUCT, $M (2019–2024)

TABLE 26 EUROPE RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014–2018)

TABLE 27 EUROPE RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2019–2024)

TABLE 28 EUROPE RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014–2018)

TABLE 29 EUROPE RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2019–2024)

TABLE 30 EUROPE BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2014–2018)

TABLE 31 EUROPE BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2019–2024)

TABLE 32 EUROPE BIOSIMILARS MARKET, BY INDICATION, $M (2014–2018)

TABLE 33 EUROPE BIOSIMILARS MARKET, BY INDICATION, $M (2019–2024)

TABLE 34 EUROPE BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2014–2018)

TABLE 35 EUROPE BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2019–2024)

TABLE 36 EUROPE BIOSIMILARS MARKET, BY ROA, $M (2014–2018)

TABLE 37 EUROPE BIOSIMILARS MARKET, BY ROA, $M (2019–2024)

TABLE 38 EUROPE BIOSIMILARS MARKET, BY COUNTRY, $M (2014–2018)

TABLE 39 EUROPE BIOSIMILARS MARKET, BY COUNTRY, $M (2019–2024)

TABLE 40 APAC BIOSIMILARS MARKET, BY PRODUCT, $M (2014–2018)

TABLE 41 APAC BIOSIMILARS MARKET, BY PRODUCT, $M (2019–2024)

TABLE 42 APAC RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014–2018)

TABLE 43 APAC RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2019–2024)

TABLE 44 APAC RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014–2018)

TABLE 45 APAC RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2019–2024)

TABLE 46 APAC BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2014–2018)

TABLE 47 APAC BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2019–2024)

TABLE 48 APAC BIOSIMILARS MARKET, BY INDICATION, $M (2014–2018)

TABLE 49 APAC BIOSIMILARS MARKET, BY INDICATION, $M (2019–2024)

TABLE 50 APAC BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2014–2018)

TABLE 51 APAC BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2019–2024)

TABLE 52 APAC BIOSIMILARS MARKET, BY ROA, $M (2014–2018)

TABLE 53 APAC BIOSIMILARS MARKET, BY ROA, $M (2019–2024)

TABLE 54 APAC BIOSIMILARS MARKET, BY COUNTRY, $M (2014–2018)

TABLE 55 APAC BIOSIMILARS MARKET, BY COUNTRY, $M (2019–2024)

TABLE 56 EXPIRATION YEAR OF SOME BIOLOGIC PATENTS IN THE U.S.

TABLE 57 BIOSIMILARS APPROVED IN CANADA

TABLE 58 NORTH AMERICA BIOSIMILARS MARKET, BY PRODUCT, $M (2014–2018)

TABLE 59 NORTH AMERICA BIOSIMILARS MARKET, BY PRODUCT, $M (2019–2024)

TABLE 60 NORTH AMERICA RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014–2018)

TABLE 61 NORTH AMERICA RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2019–2024)

TABLE 62 NORTH AMERICA RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014–2018)

TABLE 63 NORTH AMERICA RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2019–2024)

TABLE 64 NORTH AMERICA BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2014–2018)

TABLE 65 NORTH AMERICA BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2019–2024)

TABLE 66 NORTH AMERICA BIOSIMILARS MARKET, BY INDICATION, $M (2014–2018)

TABLE 67 NORTH AMERICA BIOSIMILARS MARKET, BY INDICATION, $M (2019–2024)

TABLE 68 NORTH AMERICA BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2014–2018)

TABLE 69 NORTH AMERICA BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2019–2024)

TABLE 70 NORTH AMERICA BIOSIMILARS MARKET, BY ROA, $M (2014–2018)

TABLE 71 NORTH AMERICA BIOSIMILARS MARKET, BY ROA, $M (2019–2024)

TABLE 72 NORTH AMERICA BIOSIMILARS MARKET, BY COUNTRY, $M (2014–2018)

TABLE 73 NORTH AMERICA BIOSIMILARS MARKET, BY COUNTRY, $M (2019–2024)

TABLE 74 LATAM BIOSIMILARS MARKET, BY PRODUCT, $M (2014–2018)

TABLE 75 LATAM BIOSIMILARS MARKET, BY PRODUCT, $M (2019–2024)

TABLE 76 LATAM RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014–2018)

TABLE 77 LATAM RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2019–2024)

TABLE 78 LATAM RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014–2018)

TABLE 79 LATAM RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2019–2024)

TABLE 80 LATAM BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2014–2018)

TABLE 81 LATAM BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2019–2024)

TABLE 82 LATAM BIOSIMILARS MARKET, BY INDICATION, $M (2014–2018)

TABLE 83 LATAM BIOSIMILARS MARKET, BY INDICATION, $M (2019–2024)

TABLE 84 LATAM BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2014–2018)

TABLE 85 LATAM BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2019–2024)

TABLE 86 LATAM BIOSIMILARS MARKET, BY ROA, $M (2014–2018)

TABLE 87 LATAM BIOSIMILARS MARKET, BY ROA, $M (2019–2024)

TABLE 88 LATAM BIOSIMILARS MARKET, BY COUNTRY, $M (2014–2018)

TABLE 89 LATAM BIOSIMILARS MARKET, BY COUNTRY, $M (2019–2024)

TABLE 90 MEA BIOSIMILARS MARKET, BY PRODUCT, $M (2014–2018)

TABLE 91 MEA BIOSIMILARS MARKET, BY PRODUCT, $M (2019–2024)

TABLE 92 MEA RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014–2018)

TABLE 93 MEA RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2019–2024)

TABLE 94 MEA RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014–2018)

TABLE 95 MEA RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2019–2024)

TABLE 96 MEA BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2014–2018)

TABLE 97 MEA BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2019–2024)

TABLE 98 MEA BIOSIMILARS MARKET, BY INDICATION, $M (2014–2018)

TABLE 99 MEA BIOSIMILARS MARKET, BY INDICATION, $M (2019–2024)

TABLE 100 MEA BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2014–2018)

TABLE 101 MEA BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2019–2024)

TABLE 102 MEA BIOSIMILARS MARKET, BY ROA, $M (2014–2018)

TABLE 103 MEA BIOSIMILARS MARKET, BY ROA, $M (2019–2024)

TABLE 104 MEA BIOSIMILARS MARKET, BY COUNTRY, $M (2014–2018)

TABLE 105 MEA BIOSIMILARS MARKET, BY COUNTRY, $M (2019–2024)

TABLE 106 AMEGA BIOTECH – AT A GLANCE

TABLE 107 SAMSUNG BIOEPIS CO. LTD. – AT A GLANCE

TABLE 108 APPROVED PRODUCTS OF SAMSUNG BIOEPIS CO. LTD.

TABLE 109 PIPELINE PRODUCTS OF SAMSUNG BIOEPIS CO. LTD.

TABLE 110 COHERUS BIOSCIENCES INC. – AT A GLANCE

TABLE 111 COHERUS BIOSCIENCES INC. – KEY FINANCIAL SUMMARY

TABLE 112 SYNTHON HOLDING B.V. – AT A GLANCE

TABLE 113 BIOPHARMACEUTICALS OFFERED BY SYNTHON HOLDING B.V.

TABLE 114 BIOCAD – AT A GLANCE

TABLE 115 ZYDUS CADILA – AT A GLANCE

TABLE 116 ZYDUS CADILA – KEY FINANCIAL SUMMARY

TABLE 117 CELLTRION INC. – AT A GLANCE

TABLE 118 BIOSMILARS PIPELINE PRODUCTS OF CELLTRION INC.

TABLE 119 BIOLOGICS PIPELINE PRODUCTS OF CELLTRION INC.

TABLE 120 CELLTRION INC. – KEY FINANCIAL SUMMARY

TABLE 121 DR. REDDY’S LABORATORIES LTD. – AT A GLANCE

TABLE 122 DR. REDDY’S LABORATORIES LTD. – KEY FINANCIAL SUMMARY

TABLE 123 TEVA PHARMACEUTICAL INDUSTRIES LIMITED – AT A GLANCE

TABLE 124 TEVA PHARMACEUTICAL INDUSTRIES LIMITED – KEY FINANCIAL SUMMARY

TABLE 125 NOVARTIS AG – AT A GLANCE

TABLE 126 NOVARTIS AG – KEY FINANCIAL SUMMARY

TABLE 127 PFIZER INC. – AT A GLANCE

TABLE 128 PFIZER INC. – KEY FINANCIAL SUMMARY

TABLE 129 MYLAN N.V. – AT A GLANCE

TABLE 130 MYLAN N.V. – KEY FINANCIAL SUMMARY

 

LIST OF FIGURES

 

FIG 1 RESEARCH METHODOLOGY

FIG 2 REGIONAL SPLIT OF PRIMARY AND SECONDARY RESEARCH

FIG 3 BREAKDOWN OF PRIMARY RESEARCH BY REGION

FIG 4 BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT

FIG 5 BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE

FIG 6 DATA TRIANGULATION APPROACH

FIG 7 GLOBAL BIOSIMILARS MARKET SUMMARY

FIG 8 BARGAINING POWER OF BUYERS

FIG 9 BARGAINING POWER OF SUPPLIERS

FIG 10 INTENSITY OF RIVALRY

FIG 11 THREAT OF NEW ENTRANTS

FIG 12 THREAT OF SUBSTITUTES

FIG 13 POSITIVE ATTRIBUTES FOR BIOSIMILAR PRICING

FIG 14 GLOBAL BIOSIMILARS MARKET SNAPSHOT (2018)

FIG 15 GLOBAL BIOSIMILARS MARKET, BY PRODUCT, $M (2014–2024)

FIG 16 GLOBAL RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014–2024)

FIG 17 GLOBAL RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014–2024)

FIG 18 GLOBAL BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2014–2024)

FIG 19 GLOBAL BIOSIMILARS MARKET, BY INDICATION, $M (2014–2024)

FIG 20 GLOBAL BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2014–2024)

FIG 21 GLOBAL BIOSIMILARS MARKET, BY ROA, $M (2014–2024)

FIG 22 WORLDWIDE MAJOR MARKETS FOR BIOSIMILARS

FIG 23 EUROPE BIOSIMILARS MARKET SNAPSHOT

FIG 24 EUROPE BIOSIMILARS MARKET, BY PRODUCT, $M (2014–2024)

FIG 25 EUROPE RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014–2024)

FIG 26 EUROPE RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014–2024)

FIG 27 EUROPE BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2014–2024)

FIG 28 EUROPE BIOSIMILARS MARKET, BY INDICATION, $M (2014–2024)

FIG 29 EUROPE BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2014–2024)

FIG 30 EUROPE BIOSIMILARS MARKET, BY ROA, $M (2014–2024)

FIG 31 EUROPE BIOSIMILARS MARKET, BY COUNTRY, $M (2014–2024)

FIG 32 APAC BIOSIMILARS MARKET SNAPSHOT

FIG 33 APAC BIOSIMILARS MARKET, BY PRODUCT, $M (2014–2024)

FIG 34 APAC RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014–2024)

FIG 35 APAC RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014–2024)

FIG 36 APAC BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2014–2024)

FIG 37 APAC BIOSIMILARS MARKET, BY INDICATION, $M (2014–2024)

FIG 38 APAC BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2014–2024)

FIG 39 APAC BIOSIMILARS MARKET, BY ROA, $M (2014–2024)

FIG 40 APAC BIOSIMILARS MARKET, BY COUNTRY, $M (2014–2024)

FIG 41 NORTH AMERICA BIOSIMILARS MARKET SNAPSHOT

FIG 42 NORTH AMERICA BIOSIMILARS MARKET, BY PRODUCT, $M (2014–2024)

FIG 43 NORTH AMERICA RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014–2024)

FIG 44 NORTH AMERICA RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014–2024)

FIG 45 NORTH AMERICA BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2014–2024)

FIG 46 NORTH AMERICA BIOSIMILARS MARKET, BY INDICATION, $M (2014–2024)

FIG 47 NORTH AMERICA BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2014–2024)

FIG 48 NORTH AMERICA BIOSIMILARS MARKET, BY ROA, $M (2014–2024)

FIG 49 NORTH AMERICA BIOSIMILARS MARKET, BY COUNTRY, $M (2014–2024)

FIG 50 LATAM BIOSIMILRS MARKET SNAPSHOT

FIG 51 LATAM BIOSIMILARS MARKET, BY PRODUCT, $M (2014–2024)

FIG 52 LATAM RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014–2024)

FIG 53 LATAM RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014–2024)

FIG 54 LATAM BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2014–2024)

FIG 55 LATAM BIOSIMILARS MARKET, BY INDICATION, $M (2014–2024)

FIG 56 LATAM BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2014–2024)

FIG 57 LATAM BIOSIMILARS MARKET, BY ROA, $M (2014–2024)

FIG 58 LATAM BIOSIMILARS MARKET, BY COUNTRY, $M (2014–2024)

FIG 59 MEA BIOSIMILARS MARKET SNAPSHOT

FIG 60 MEA BIOSIMILARS MARKET, BY PRODUCT, $M (2014–2024)

FIG 61 MEA RECOMBINANT GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014–2024)

FIG 62 MEA RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET, BY TYPE, $M (2014–2024)

FIG 63 MEA BIOSIMILARS MARKET, BY TECHNOLOGY, $M (2014–2024)

FIG 64 MEA BIOSIMILARS MARKET, BY INDICATION, $M (2014–2024)

FIG 65 MEA BIOSIMILARS MARKET, BY MANUFACTURING TYPE, $M (2014–2024)

FIG 66 MEA BIOSIMILARS MARKET, BY ROA, $M (2014–2024)

FIG 67 MEA BIOSIMILARS MARKET, BY COUNTRY, $M (2014–2024)

FIG 68 BENCHMARKING OF KEY PLAYERS

FIG 69 ZYDUS CADILA – REVENUE SPLIT BY GEOGRAPHY (2018)

FIG 70 CELLTRION INC. – REVENUE SPLIT BY SEGMENT (2017)

FIG 71 DR. REDDY’S LABORATORIES LTD. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2018)

FIG 72 TEVA PHARMACEUTICAL INDUSTRIES LIMITED – REVENUE SPLIT BY GEOGRAPHY (2018)

FIG 73 NOVARTIS AG – REVENUE SPLIT BY MARKETED PRODUCTS AND GEOGRAPHY (2018)

FIG 74 PFIZER INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2018)

FIG 75 MYLAN N.V. – REVENUE SPLIT BY THERAPEUTIC AREA AND GEOGRAPHY (2018)

Place An Order
USD 4900 USD 5900 USD 7500
Customized Report Solution

Get a bespoke market intelligence solution

 
We are committed to ensuring the highest level of client satisfaction
Quality Acknowledgement
Quality Acknowledgement

Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you

Unmatched Standards
Unmatched Standards

Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights

Reach Us
Reach Us Whenever You Need Us

With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required

Data Security
Complete Data Security

We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws